Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Connected-Health Standards Signal US FDA's Future Thinking

Executive Summary

Standards organizations say software and informatics standards recently recognized by US FDA are a sign of the technologies the agency expects to tackle in future product applications and a signal to industry about priorities.

You may also be interested in...



Message To US Congress: Know What Cybersecurity Tools You Have, Share What You Know, Untie Our Hands

Responding to US lawmakers on how to tackle cybersecurity threats to medical devices and the health-care system, device firms, hospitals, provider groups and other stakeholders listed recommendations on creating inventories, sharing information and amending laws.

2018 An Inflection Point For mHealth After An Active Year

The past year saw US FDA and industry work hard and fast to prepare for what looks like an inevitable boom in the digital-health sector. According to interviews, the time is ripe for adoption of mobile health apps to help reduce health-care costs, but the brave new world also brings with it big challenges.

'Excellence' In Health-Software Design: US FDA Taps Nine Firms To Figure Out What That Means

The likes of Apple, Samsung and FitBit join traditional medtech players Johnson & Johnson and Roche, along with digital-health startups in a new US FDA pilot program intended to define best-practice software design as a means to "pre-certify" companies and reduce pre-market requirements. FDA's Bakul Patel and the CEO of one pilot participant, Pear Therapeutics, weighs in.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT121624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel